Akebia Therapeutics (AKBA) Total Liabilities (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Total Liabilities data on file, last reported at $335.1 million in Q1 2026.

• On a quarterly basis, Total Liabilities rose 17.35% year-over-year to $335.1 million in Q1 2026; TTM through Mar 2026 was $335.1 million, a 17.35% increase from a year earlier, with the FY2025 full-year figure at $344.0 million, up 27.46% from the prior year.
• Total Liabilities for Q1 2026 stood at $335.1 million, down from $344.0 million in the prior quarter.
• Over the last five years, Total Liabilities for AKBA reached as high as $519.2 million in Q1 2022 and fell as low as $252.7 million in Q1 2024.
• Historically, Total Liabilities has averaged $326.0 million across 5 years, with a median of $300.1 million in 2023.
• Across the five-year window, Total Liabilities sank 42.21% in 2023 and advanced 27.46% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $350.8 million in 2022, then declined by 22.39% to $272.3 million in 2023, then dropped by 0.89% to $269.9 million in 2024, then rose by 27.46% to $344.0 million in 2025, then decreased by 2.56% to $335.1 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $335.1 million in Q1 2026, $344.0 million in Q4 2025, and $322.6 million in Q3 2025.